These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 4024909

  • 1. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I, Schalén L, Jäntti V.
    Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909
    [Abstract] [Full Text] [Related]

  • 2. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I, Padoan S, Schalén L, Lyttkens L, Magnusson M, Henriksson NG.
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [Abstract] [Full Text] [Related]

  • 3. Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on different types of nystagmus.
    Pyykkö I, Schalén L, Matsuoka I.
    Acta Otolaryngol; 1985 Aug; 99(5-6):597-604. PubMed ID: 4024910
    [Abstract] [Full Text] [Related]

  • 4. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME, Royal JW, Shaw JE, Schmitt LG.
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [Abstract] [Full Text] [Related]

  • 5. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S, Shapira S, Zilbiger A, Ribak J.
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [Abstract] [Full Text] [Related]

  • 6. A reduction of vestibulo-visual integration during transdermally administered scopolamine and dimenhydrinate. A presentation of gain control theory in motion sickness.
    Pyykkö I, Schalén L, Jäntti V, Magnusson M.
    Acta Otolaryngol Suppl; 1984 Nov; 406():167-73. PubMed ID: 6332454
    [Abstract] [Full Text] [Related]

  • 7. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z, Shupak A, Gordon CR.
    Clin Pharmacokinet; 2006 Nov; 45(6):543-66. PubMed ID: 16719539
    [Abstract] [Full Text] [Related]

  • 8. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine.
    Schmitt LG, Shaw JE.
    Arch Otolaryngol Head Neck Surg; 1986 Jan; 112(1):88-91. PubMed ID: 3940518
    [Abstract] [Full Text] [Related]

  • 9. Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study.
    Ercin D, Erdur B, Turkcuer I, Seyit M, Ozen M, Yilmaz A, Zincir Ercin DO.
    Am J Emerg Med; 2021 Feb; 40():77-82. PubMed ID: 33360021
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study.
    Pytel J, Nagy G, Tóth A, Spellenberg S, Schwarz M, Répassy G.
    Clin Ther; 2007 Jan; 29(1):84-98. PubMed ID: 17379049
    [Abstract] [Full Text] [Related]

  • 11. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions].
    Offenloch K, Zahner G, Dietlein G, Franz I.
    Arzneimittelforschung; 1986 Sep; 36(9):1401-6. PubMed ID: 3539128
    [Abstract] [Full Text] [Related]

  • 12. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF, Bongaerts MC, Christiaanse JC, Hofkamp HG, van Ouwerkerk W.
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [Abstract] [Full Text] [Related]

  • 13. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G.
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [Abstract] [Full Text] [Related]

  • 14. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A.
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD, Oertel R, Kirch W.
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [Abstract] [Full Text] [Related]

  • 16. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interaction of alcohol and transdermally administered scopolamine.
    Gleiter CH, Antonin KH, Schoenleber W, Bieck PR.
    J Clin Pharmacol; 1988 Dec; 28(12):1123-7. PubMed ID: 3243930
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effectiveness of intravenous piracetam and intravenous dimenhydrinate in the treatment of acute peripheral vertigo in the emergency department.
    Ozdemir H, Akinci E, Coskun F.
    Singapore Med J; 2013 Nov; 54(11):649-52. PubMed ID: 24276103
    [Abstract] [Full Text] [Related]

  • 20. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study.
    Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ.
    Clin Ther; 2004 Jun; 26(6):866-77. PubMed ID: 15262457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.